Blog

John V. Oyler: Committed to uniting the global community against cancer as BeOne

BeiGene/LinkedIn

Nov 16, 2024, 11:27

John V. Oyler: Committed to uniting the global community against cancer as BeOne

John V. Oyler, Founder, Chairman & CEO at BeiGene, shared a post by BeiGene on LinkedIn, adding the following:

“We must all work together, which is why we are committed to uniting the global community against cancer as BeOne. Learn more about our proposed company name change by reading the press release below.”

Quoting BeiGene’s post:

“Today we unveiled our proposed name change to BeOne Medicines Ltd. Reaffirming our mission to unite the global community against cancer. Read the press release for full details.”

BeiGene BeOne Medicines Biopharma cancer cancer care Cancer research cancer treatment clinical trials drug development global community global oncology healthcare Healthcare Partnerships OncoDaily Oncology oncology research patient care pharmaceutical innovation

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage